Image
Clinical Issues

Clinical Issues in Alzheimer's Disease

Debates and Discussions About Diagnosis, New Therapies, and Health Care Delivery

Meeting Slides

Suggested Readings

2022 Alzheimer’s disease facts and figures.

Alzheimer’s Association.

The Alzeimer's disease clinical spectrum: diagnosis and management.

Atri A. Med Clin North Am. 2019;103(2):263-293.

Neuropathological stageing of Alzheimer-related changes.

Braak H, Braak E. Acta Neuropathol. 1991;82(4):239-259.

Two randomized phase 3 studies of aducanumab in early Alzheimer's disease.

Budd Haeberlein S, Aisen PS, Barkhof F. et al. J Prev Alzheimers Dis. 2022;9 (2): 197-210.

Costly new Alzheimer disease medications on the horizon—financing alternatives for Medicare.

Fleming WK, Brown CR, Shrank WH. JAMA Health Forum. 2020;1(9):e201148.

Assessment of a plasma amyloid probabilty score to estimate amyloid positron emission tomography findings among adults with cognitive impariment.

Hu Y, Kirmess KM, Meyer MR, et al. JAMA Netw Open. 2022;5(4):e228392.

Pharmacotherapy of Alzheimer's disease: seeking clarity in a time of uncertainty.

Husna Ibrahim N, Yahaya MF, Mohamed W, et al. Front Pharmacol. 2020;11:261.

A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers.

Jack CR Jr, Bennett DA, Blennow K, et al. Neurology. 2016;87(5):539-547.

Molecular biomarkers of Alzheimer's disease: progress and prospects.

Lashley T, Schott JM, Weston P, et al. Dis Model Mech. 2018;11(5):dmm031781.

Neuroinflammation and microglial activiation in Alzheimer disease: where do we go from here?

Leng F, Edison P. Nat Rev Neurol. 2021;17(3):157-172.

Donanemab in early Alzheimer's disease.

Mintun MA, Lo AC, Duggan Evans C, et al. N Engl J Med. 2021;384(18):1691-1704.

Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.

Palmqvist S, Tideman P, Cullen N, et al. Nat Med. 2021;27(6):1034-1042.

Increasing precision of clinical diagnosis of Alzheimer's disease using a combined algorithm incorporating clinical and novel biomarker data.

Sabbagh MN, Lue LF, Fayard D, Shi J. Neurol Ther. 2017;6(suppl 1):83-95.

Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease.

Salloway S, Chalkias S, Barkhof F, et al. JAMA Neurol. 2022;79(1):13-21.

Cognitive assessment of Alzheimer's disease and dementias in clinical practice: pragmatics of brief instruments and neuropsychological evaluation. 

Shaughnessy L, Sheard S, Goldfarb D, Atri A. J Clin Psychiatry. 2019;8-(4):MS18002Br2C. 

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

Swanson CJ, Zhang Y, Dhadda S, et al. Alzheimers Res Ther. 2021;13(1):80.

What are the difficulties of implementing innovative pharmacy practice models in the care of patients with dementia?

Wimo A. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1):1-4.

Economic burden of Alzheimer disease and managed care considerations.

Wong W. Am J Manag Care. 2020;26(suppl 8):S177-S183.

Activity
Activity for event:Clinical Issues in Alzheimer’s Disease

Debates and Discussions About Diagnosis, New Therapies, and Healthcare Delivery

Activity
Activity for event:Clinical Issues in Alzheimer’s Disease

Debates and Discussions About Diagnosis, New Therapies, and Healthcare Delivery

Activity
Activity for event:Clinical Issues in Alzheimer’s Disease

Debates and Discussions About Diagnosis, New Therapies, and Healthcare Delivery

Relevant Resources

Updates on the Diagnosis and Management of Alzheimer's Disease

Screening, Imaging, and Emerging Treatment Strategies

Finding the Path in Alzheimer’s Disease

Early Diagnosis to Ongoing Collaborative Care

Expert Consult Series in Multiple Sclerosis

Updates, Clinical Scenarios, and Future Directions

Moving Forward in Alzheimer’s Disease

New Management Paradigms for Patients and Healthcare Systems